|
| Human HPV16 E7 (HLA-A*02:01) Protein (LTP10157) |
|
| LTP10157 |
|
| 100ug |
|
|
$406 In stock |
| HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. |
| Recombinant Human HPV16 E7(HLA-A*02:01) Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and YMLDLQPET peptide. |
|
| HPV16 E7 (HLA-A*02:01) |
|
| Human |
|
| P04439-1(HLA-A*02:01)&P61769(B2M)&YMLDLQPET peptide |
|
| Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide |
|
| The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-His-Avi |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
